A GP IIIa ligand-induced binding site antibody detects multiple GP IIb-IIIa conformations, and its binding is modulated by various ligands.
Heath
T L
TL
Department of Medicine, University of Tennessee, Memphis 38163.
Wall
C D
CD
Jennings
L K
LK
D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000494:pharmacology; D001666:Binding Sites, Antibody; D001792:Blood Platelets / Q000378:metabolism*; D000939:Epitopes / Q000032:analysis; D016326:Extracellular Matrix Proteins / Q000494:pharmacology; D005353:Fibronectins / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008024:Ligands; D009842:Oligopeptides / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010980:Platelet Membrane Glycoproteins / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium; D019096:Vitronectin; D014841:von Willebrand Factor / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D006023:Glycoproteins; D008024:Ligands; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D019096:Vitronectin; D014841:von Willebrand Factor; D014316:Tritium; C046617:arginyl-glycyl-aspartyl-serine